• Search
  • Login
  • Register
Menu
  • Last issue
  • Home
  • News
  • CongressUpdate
  • Guidelines
  • Specials
  • Links
  • Reimbursement News
All
  • All
  • BJH articles
  • Blog articles
  • Specials
Forgot Password? Not a member yet? Register here

Category

All
  • Alle
  • General
  • Healthy Living
  • Pharma News
  • Health of Tomorrow
  • Viewpoints
  • Art Corner
  • Fundraising
  • Prevention
  • Science
  • Clinical trials
  • Clinical practice
  • Corona
  • Medical Research
  • Health Innovation
  • Art on View
  • Podcasts
  • Therapy
  • Editor's pick
  • Covid-19
  • Society Announcement
  • Reimbursement News
  • Congress News

Specialty

All
  • Alle
  • YESCARTA
  • BEKEMV
  • NPLATE
Medical Research

Green tea compound could be gateway towards new cancer drugs

subscribe Latest issue All issues Newsletters
Index latest issue
  • INTRODUCTION
  • Advancements in thrombophilia testing: The role of multi-gene panels in venous thromboembolism
  • The role of UBTF-TD mutations in paediatric acute myeloid leukaemia and myelodysplastic syndrome
  • Desensitisation as treatment option in patients with drug hypersensitivity
  • HMB-001: Novel treatment for Glanzmann thrombasthenia
  • Anti-IL6 receptor antibody for the treatment of immune checkpointrelated hemophagocytic lymphohistiocytosis
  • Highlights from EBMT 2025
  • Journal scan
  • New haematology reimbursements in Belgium
Fundraising

Unmasking cancer: new website focuses on various aspects of the disease and its impact

Clinical practice

New prognostic index for Burkitt lymphoma

Clinical trials

Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors

Science

Can an existing diabetes medicine prevent graft-versus-host disease after stem cell transplant...

ASH 2020

Asciminib as a third line treatment for chronic phase chronic myeloid leukaemia

ASH 2020

Gene therapy offers new perspectives in treatment of haemophilia B

Previous 45 46 47 48 49 50 51 Next
Top

Join our newsletter

  • This field is for validation purposes and should be left unchanged.
  • About BJH
  • Advertisements & sponsoring
  • Vacancies
  • Disclaimer
  • Privacy
  • Contact

BJH is published by Ariez International BV, Westzijde 22, 1506 EE Zaandam, The Netherlands

© BJH 2025